PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Medigene AG

26.01.2004 – 08:03

Medigene AG

euro adhoc: MediGene AG
MediGene Receives Approval for the Three-Months Sustained Release Product Eligard® (previously known as Leuprogel®) (E)

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Martinsried - San Diego, January 26, 2004: The German-American
biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG)
has received marketing authorization for Germany from the
Bundesinstitut für Arzneimittel und Medizinprodukte (= Federal
Institute for pharmaceuticals and medical devices), BfArM, for the
three-months sustained release product of the anti-cancer drug
Eligard® (previously known as Leuprogel®) for the treatment of
advanced prostate cancer. The corresponding one-month sustained
release product of this drug had received marketing authorization at
the beginning of December 2003. The three-months sustained release
product offers additional applications of Eligard®, thus enhancing
its competitiveness. As announced on January 14, MediGene's partner
Yamanouchi will take on market launch and sale of Eligard®. As part
of the agreement with Yamanouchi, MediGene will receive a milestone
payment for this approval of the three-months sustained release
product.
MediGene and Yamanouchi are planning to submit marketing
authorization applications in other European countries as well.
Within the framework of the so-called "Mutual Recognition Procedure",
the German approval will serve as a reference there. MediGene had
acquired the license for commercialization of Eligard® in Europe from
the US company Atrix Laboratories, Inc. in April 2001.
Contact:
MediGene AG, Email: investor@medigene.com, Fax: ++49-89-8565-2920
Julia Hofmann, Public Relations, ph.: ++49-89-8565-3324 
Dr. Michael Nettersheim, Investor Relations, ph.:++49-89-8565-2946
end of announcement        euro adhoc 26.01.2004

Further inquiry note:

Jessica Kern
Tel.: +49 (0)89 8565 2986
E-mail: j.kern@medigene.com

Branche: Biotechnology
ISIN: DE0005020903
WKN: 502090
Index: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Niedersächsische Börse zu Hannover / free trade
Berliner Wertpapierbörse / free trade
Bayerische Börse / free trade
Hamburger Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Baden-Württembergische Wertpapierbörse / free trade

Original content of: Medigene AG, transmitted by news aktuell

More stories: Medigene AG
More stories: Medigene AG